Latest Headlines
-
Honeywell Announces Upcoming Webinar and Conference Schedule
3/19/2024
Visit us at Booth 17 to learn more about our unified manufacturing operations platform and how it accelerates innovation and increases efficiency, quality, and compliance.
-
Manufacturing Gene Therapy For Early-Onset Metachromatic Leukodystrophy
3/19/2024
AGC Biologics received U.S. Food and Drug Administration (FDA) clearance at the company’s Milan site to begin commercial manufacturing for the lentiviral vector and genetically modified cell drug product (DP) of Orchard Therapeutics’ Lenmeldy™ (atidarsagene autotemcel), a hematopoietic stem cell (HSC) gene therapy for the treatment of pre-symptomatic late infantile, pre-symptomatic early juvenile and early symptomatic early juvenile metachromatic leukodystrophy (MLD).
-
Pluri Selected As CDMO By Remedy Cell For Cell-Derived Cell-Free Drug Manufacturing
3/14/2024
Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions, today announced that its CDMO division (PluriCDMO™) has signed a manufacturing agreement with Remedy Cell Ltd, an innovative, biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions.
-
AES Clean Technology Appoints New Vice President Of Engineering
2/22/2024
AES Clean Technology, a leading provider of high-performance modular cleanroom facilities, has appointed Chris Barbieri as Vice President of Engineering.
-
WuXi Advanced Therapies Receives FDA Approval To Manufacture Iovance’s AMTAGVI™ (lifileucel) For Advanced Melanoma
2/20/2024
WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced that the U.S. Food and Drug Administration (FDA) has approved its Philadelphia site to begin the analytical testing and manufacturing of AMTAGVI for Iovance, which received FDA accelerated approval of its Biologics License Application (BLA) on February 16, 2024.
-
CURIS System And AST Unite To Redefine Aseptic Fill-Finish Processing Technology
2/5/2024
CURIS System, an innovator in advanced decontamination technology, and AST, a leader in aseptic fill-finish processing technology, today announced a groundbreaking partnership. This collaboration marks a significant step forward in the pharmaceutical manufacturing industry, as the two companies combine technology to revolutionize the biodecontamination of aseptic fill-finish isolators using CURIS's disruptive vapor decontamination technology.
-
Novo Holdings To Acquire CDMO Catalent Pharma Solutions For $16.5 Billion
2/5/2024
Catalent, Inc. (NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, today announced that they have entered into a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion on an enterprise value basis.
-
Solesis, Parent Company of Charter Medical, to Expand Single-use Manufacturing Capabilities into Costa Rica
2/2/2024
The site will expand capabilities to enable development in the fast-growing cardiovascular and advanced therapy markets.
- IDT Biologika Receives CDMO Leadership Awards 2024 In Six Categories 2/2/2024
-
Cleanroom Leader AES Clean Technology Announces New Vice President Of Construction
2/1/2024
A leading provider of high-performance cleanroom facilities, AES Clean Technology, has announced the appointment of John Costalas to its senior leadership team as Vice President of Construction.